Literature DB >> 26642335

When is second allogeneic HSCT for relapse of acute leukaemia an option?

M Christopeit1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26642335     DOI： 10.1038/bmt.2015.285

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  17 in total

1.  Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO).

Authors:  A Bosi; S Bacci; R Miniero; F Locatelli; D Laszlo; G Longo; A Busca; M T Van Lint; P Di Bartolomeo; A Amici
Journal:  Leukemia       Date:  1997-03       Impact factor: 11.528

2.  Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation.

Authors:  A Bosi; D Laszlo; M Labopin; J Reffeirs; M Michallet; E Gluckman; P E Alessandrino; F Locatelli; J P Vernant; J Sierra; J P Jouet; F Frassoni
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

3.  Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

Authors:  Thomas Schroeder; Elena Rachlis; Gesine Bug; Matthias Stelljes; Stefan Klein; Nina Kristin Steckel; Dominik Wolf; Mark Ringhoffer; Akos Czibere; Kathrin Nachtkamp; Ariane Dienst; Mustafa Kondakci; Michael Stadler; Uwe Platzbecker; Lutz Uharek; Thomas Luft; Roland Fenk; Ulrich Germing; Martin Bornhäuser; Nicolaus Kröger; Dietrich W Beelen; Rainer Haas; Guido Kobbe
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-23       Impact factor: 5.742

4.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

5.  Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.

Authors:  G Andreola; M Labopin; D Beelen; P Chevallier; R Tabrizi; A Bosi; M Michallet; S Santarone; G Ehninger; E Polge; D Laszlo; C Schmid; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

6.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.

Authors:  M Eapen; S A Giralt; M M Horowitz; J P Klein; J E Wagner; M-J Zhang; M S Tallman; D I Marks; B M Camitta; R E Champlin; O Ringdén; C N Bredeson; R Martino; R P Gale; M S Cairo; M R Litzow; M deLima
Journal:  Bone Marrow Transplant       Date:  2004-10       Impact factor: 5.483

7.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  A Gratwohl; J Hermans; J M Goldman; W Arcese; E Carreras; A Devergie; F Frassoni; G Gahrton; H J Kolb; D Niederwieser; T Ruutu; J P Vernant; T de Witte; J Apperley
Journal:  Lancet       Date:  1998-10-03       Impact factor: 79.321

8.  Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.

Authors:  P Christopoulos; C Schmoor; M Waterhouse; R Marks; R Wäsch; H Bertz; J Finke
Journal:  Bone Marrow Transplant       Date:  2013-02-04       Impact factor: 5.483

9.  Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.

Authors:  T Ruutu; L C de Wreede; A van Biezen; R Brand; M Mohty; P Dreger; R Duarte; C Peters; L Garderet; S Schönland; A Gratwohl; D Niederwieser; T de Witte; N Kröger
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

10.  Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.

Authors:  Maximilian Christopeit; Oliver Kuss; Jürgen Finke; Ulrike Bacher; Dietrich Wilhelm Beelen; Martin Bornhäuser; Rainer Schwerdtfeger; Wolfgang Andreas Bethge; Nadezda Basara; Martin Gramatzki; Johanna Tischer; Hans-Jochem Kolb; Lutz Uharek; Ralf G Meyer; Donald Bunjes; Christof Scheid; Hans Martin; Dietger Niederwieser; Nicolaus Kröger; Hartmut Bertz; Hubert Schrezenmeier; Christoph Schmid
Journal:  J Clin Oncol       Date:  2013-08-05       Impact factor: 44.544
View more
  1 in total

Review 1.  The role of second transplants for leukemia.

Authors:  Daniel Weisdorf
Journal:  Best Pract Res Clin Haematol       Date:  2016-10-19       Impact factor: 3.020
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.